STUDI PEMANFAATAN ANTIBODI MONOKLONAL SEBAGAI TERAPI DAN DIAGNOSIS PADA PASIEN : ARTIKEL REVIEW

Authors

  • Rizma Kurniawati Yuningsih Program Studi Farmasi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram, NTB, Indonesia
  • Kalisa Attaya Program Studi Farmasi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram, NTB, Indonesia
  • Nur Tahany Yustitia Program Studi Farmasi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram, NTB, Indonesia
  • Raehanul Maziya Program Studi Farmasi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram, NTB, Indonesia
  • Widi Gustita Utari Program Studi Farmasi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram, NTB, Indonesia
  • Anggit Listyacahyani Program Studi Farmasi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram, NTB, Indonesia

DOI:

https://doi.org/10.31004/jkt.v6i2.45406

Keywords:

antibodi monoclonal, diagnosis, terapi

Abstract

Antibodi monoklonal adalah protein yang diproduksi dari satu klon sel dan diklasifikasikan ke dalam empat jenis: murine, chimeric, humanized, dan antibodi manusia. Artikel ini bertujuan untuk meninjau pemanfaatan antibodi monoklonal dalam terapi dan diagnosis berbagai penyakit. Metode yang digunakan adalah Systematic Literature Review dari 13 artikel ilmiah yang diperoleh melalui database seperti PubMed, Google Scholar, dan ScienceDirect. Hasil studi menunjukkan bahwa antibodi monoklonal efektif dalam mendiagnosis penyakit menular (seperti MERS-CoV, TBC, malaria, zika, schistosomiasis) dan tidak menular (seperti penyakit Parkinson dan Alzheimer), dengan memanfaatkan interaksi spesifik antara antibodi-antigen melalui teknik seperti ELISA dan imunokromatografi. Sebagai terapi, antibodi ini digunakan untuk menangani berbagai penyakit seperti Alzheimer, asma, migrain vestibular, sepsis, HIV-1, rheumatoid arthritis, dan penyakit mata. Beberapa antibodi bekerja dengan mengikat target seperti amiloid, IL-13, CGRP, atau TNF-α untuk memodulasi respons imun dan mengurangi gejala penyakit. Efektivitas dan spesifisitas tinggi dari antibodi monoklonal menjadikannya alat penting dalam bidang kedokteran modern, baik dalam mendiagnosis secara akurat maupun memberikan terapi yang ditargetkan dengan efek samping minimal.

References

Ayón, C., Castán, D., Mora, A., Naranjo, D., Obando, F., & Mora, J. J. (2022). Monoclonal Antibodies: A Therapeutic Option for the Treatment of Ophthalmic Diseases of the Eye Posterior Segment. Borneo Journal of Pharmacy, 5(3), 229-246.

Beccari, M. V., Mogle, B. T., Sidman, E. F., Mastro, K. A., Asiago-Reddy, E., & Kufel, W. D. (2019). Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. Antimicrobial agents and chemotherapy, 63(6), 10-1128.

Codices, V., Matos, O., & Novo, C. (2013). Monoclonal antibody technology applied to the detection of <i>Cryptosporidium parvum</i> oocysts in human and cattle fecal samples. Advances in Bioscience and Biotechnology, 04(04), 7–16. https://doi.org/10.4236/abb.2013.44a002.

Cohen, M. D., & Keystone, E. (2015). Rituximab for rheumatoid arthritis. Rheumatology and therapy, 2, 99-111.

Edris, A., De Feyter, S., Maes, T., Joos, G., & Lahousse, L. (2019). Monoclonal antibodies in type 2 asthma: A systematic review and network meta-analysis. Respiratory Research, 20(1), 1–15. https://doi.org/10.1186/s12931-019-1138-3.

Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., ... & Rutgeerts, P. (2016). Ustekinumab as induction and maintenance therapy for Crohn’s disease. New England Journal of medicine, 375(20), 1946-1960.

Frosolini, A., & Lovato, A. (2024). Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis. Indian Journal of Otolaryngology and Head and Neck Surgery, 76(4), 3737–3744. https://doi.org/10.1007/s12070-024-04578-y.

Grenfell, R. F. Q., Coelho, P. M. Z., Taboada, D., De Mattos, A. C. A., Davis, R., & Harn, D. A. (2014). Newly established monoclonal antibody diagnostic assays for Schistosoma mansoni direct detection in areas of low endemicity. PLoS ONE, 9(1), 1–8. https://doi.org/10.1371/journal.pone.0087777.

Guliy, O. I., Khanadeev, V. A., & Dykman, L. A. (2024). Phage Antibodies for Detection of Diagnostically Important Antigens. Frontiers in Bioscience - Elite, 16(3), 1–15. https://doi.org/10.31083/j.fbe1603024.

Hidayah, A. P., Miftah, A. M., & Faqih, T. M. (2020). Studi Interaksi Antibodi Monoklonal ZV-2 dan ZV-48 terhadap Protein E (DIII) Virus Zika secara In Silico. Prosiding Farmasi, 6(2), 461-467.

Indiastari, D., Winarsih, S., & Fitri, L. E. (2018). Deteksi Protein 270 kDa Plasmodium falciparum Isolat Malang pada Membran Eritrosit Penderita Malaria dengan Komplikasi. Pustaka Kesehatan, 6(2), 331. https://doi.org/10.19184/pk.v6i2.7785.

Li, H., Wang, K., Huang, H., Cheng, W., & Liu, X. (2019). A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma. PLoS ONE, 14(1), 1–13. https://doi.org/10.1371/journal.pone.0211790.

Mahdizade Ari, M., Amini, M. E., Sholeh, M., & Zahedi Bialvaei, A. (2024). The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review. New Microbes and New Infections, 60–61(March), 101435. https://doi.org/10.1016/j.nmni.2024.101435.

Mansour, I., Murugapandian, S., Tanriover, B., & Thajudeen, B. (2023). Contemporary Monoclonal Antibody Utilization in Glomerular Diseases. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 7(4), 276–290. https://doi.org/10.1016/j.mayocpiqo.2023.04.00.

Margalin, B., Lestari, D. Y., Kusmala, Y. Y., Wedarti, Y. R., Roza, R., Ratri, A. K., ... & Hardianti, B. (2023). Pengantar Imunologi Kanker.

Moradi-Sardareh, H., Moradi, M., Bordbar, E., Malekpour, M., Bagheri, S., Nakhodazadeh, N., Rahbar, S., & Farhadian Asgarabadi, J. (2016). The Use of Monoclonal Antibodies in the Treatment of Alzheimer Disease. Asian Pacific Journal of Cancer Biology, 1(3), 59–66. https://doi.org/10.31557/apjcb.2016.1.3.59-66.

Nielsen, J., Lauritsen, J., Pedersen, J. N., Nowak, J. S., Bendtsen, M. K., Kleijwegt, G., Lusser, K., Pitarch, L. C., Moreno, J. V., Schneider, M. M., Krainer, G., Goksøyr, L., Khalifé, P., Kaalund, S. S., Aznar, S., Kjærgaard, M., Sereikaité, V., Strømgaard, K., Knowles, T. P. J., … Otzen, D. E. (2024). Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomers. Npj Parkinson’s Disease, 10(1), 1–26. https://doi.org/10.1038/s41531-024-00747-6.

Satyagraha, M. T., Sheridan, G., Laryan, V. E. A., & Hidayatullah, G. C. S. (2022). Tocilizumab As Monoclonal Antibody Therapy in Overcoming Acute Respiratory Distress Syndrome in Covid-19 Patients. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 9(3), 92–101. https://doi.org/10.53366/jimki.v9i3.488.

Silva, I. B. B., da Silva, A. S., Cunha, M. S., Cabral, A. D., de Oliveira, K. C. A., De Gaspari, E., & Prudencio, C. R. (2020). Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools. Journal of Venomous Animals and Toxins Including Tropical Diseases, 26(November 2020), 1–12. https://doi.org/10.1590/1678-9199-JVATITD-2020-0019.

Suharti, N., Darwin, E., Manaf, A., Marlina, & Putra, A. E. (2014). Assessing the diagnostic potential of monoclonal antibodies against 20 kDa M. tuberculosis protein as candidate diagnostic method for M. tuberculosis through sputum. Pakistan Journal of Medical Research, 53(2), 30–34. https://search.bvsalud.org/gim/resource/en/emr-196829.

Wiguna, V. V., Haq, A. D., & Rahayu, L. A. D. (2021). Antibodi Monoklonal Anti-CD3 Sebagai Terapi Diabetes Mellitus Tipe 1: Sebuah Kajian Sistematis dan Meta-analisis. Unram Medical Journal, 10(3), 581–593. https://doi.org/10.29303/jku.v10i3.580.

Yamaoka, Y., Matsuyama, S., Fukushi, S., Matsunaga, S., Matsushima, Y., Kuroyama, H., Kimura, H., Takeda, M., Chimuro, T., & Ryo, A. (2016). Development of monoclonal antibody and diagnostic test for Middle East respiratory syndrome coronavirus using cell-free synthesized nucleocapsid antigen. Frontiers in Microbiology, 7(APR), 1–15. https://doi.org/10.3389/fmicb.2016.0050.

Downloads

Published

2025-06-06

Issue

Vol. 6 No. 2 (2025): JUNI 2025

Section

Articles

License

Copyright (c) 2025 Rizma Kurniawati Yuningsih, Kalisa Attaya, Nur Tahany Yustitia, Raehanul Maziya, Widi Gustita Utari, Anggit Listyacahyani

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).